In the current study, we examined whether genetic polymorphisms in ABCB1, ABCC1, ABCC2, and ABCG2 genes may have an impact on the outcome of CML patients treated with nilotinib. The gene discussed is ABCG2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.